beta-Catenin Antibody

Flow Cytometry: beta-Catenin Antibody [NBP1-32239] - HeLa cell.Black: Unlabelled sample was used as a control. Red: beta Catenin antibody [N1N2-2], N-term dilution: 1:50.Acquisition of 20,000 events were collected using a Dylight 488-conjugated secondary antibody for FACS analysis.

Chromatin Immunoprecipitation (ChIP): beta-Catenin Antibody [NBP1-32239] - Cross-linked ChIP was performed with HCT116 chromatin extract and 5 ug of either control rabbit IgG or anti-beta Catenin antibody. The precipitated DNA was detected by PCR with primer set targeting to c-Myc promoter.

Western Blot: beta-Catenin Antibody [NBP1-32239] - Western blot for beta-catenin in HEK 293 cells treated with LiCl (10mM) for 1 hr. Image from verified customer review.

Western Blot: beta-Catenin Antibody [NBP1-32239] - Sample (50 ug of whole cell lysate) A: mouse brain 7.5% SDS PAGE diluted at 1:1000

Western Blot: beta-Catenin Antibody [NBP1-32239] - A. 30 ug PC-12 whole cell lysate/extract 7.5 % SDS-PAGEbeta Catenin antibody [N1N2-2], N-term dilution: 1:1000

Western Blot: beta-Catenin Antibody [NBP1-32239] - Non-transfected (-) and transfected (+) HeLa whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with beta Catenin antibody [N1N2-2], N-term.

Immunocytochemistry/Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: beta Catenin protein stained by beta Catenin antibody [N1N2-2], N-term diluted at 1:500. Blue: Hoechst 33342 staining.

Immunocytochemistry/Immunofluorescence: beta-Catenin Antibody [NBP1-32239] - HCT 116 cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: beta Catenin protein stained by beta Catenin antibody [N1N2-2], N-term diluted at 1:500. Blue: Hoechst 33342 staining.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse colon. Green: beta Catenin antibody [diluted at 1:500. Red: alpha Tubulin antibody diluted at 1:500. Blue: Hoechst 33342 staining.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse urinary bladder diluted at 1:500.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse skin dilution: 1:500.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse colon dilution: 1:500.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse duodenum. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded human esophagus. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded human cervix. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse duodenum. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded rat colon. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded rat duodenum. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.

Immunohistochemistry-Paraffin: beta-Catenin Antibody [NBP1-32239] - Paraffin-embedded mouse intestine. beta Catenin antibody [N1N2-2], N-term diluted at 1:500.

Western Blot: beta-Catenin Antibody [NBP1-32239] -

Immunoblotting analysis of IR-induced AKT (Ser473) activation. (A) The levels of AKT activation were measured by AKT Ser473 phosphorylation in 293T, 293T/eIF3f and 293T/eIF3f-hMSH4 cells treated with 10 Gy IR in comparison to untreated controls. Levels of p53 Ser15 phosphorylation and the total protein levels of AKT, hMRE11 and p53 were also analyzed. alpha-tubulin was used as a loading control. (B) The levels of Chk2 activation (Chk2 Thr68 phosphorylation) in 293T, 293T/eIF3f and 293T/eIF3f-hMSH4 cells in response to 10 Gy IR. Cell lysates were prepared at 1 hr post IR treatment. Untreated cells were analyzed as controls, while alpha-tubulin was used as a loading control. Image collected and cropped by CiteAb from the following open publication (https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-12-51), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: beta-Catenin Antibody [NBP1-32239] -

AMPK‐activating AICAR treatment activates FANCD2, a pivotal molecule of Fanconi anemia DNA damage signaling pathway. (A) AICAR treatment induces FANCD2 monoubiquitination in transformed normal fibroblasts (GM00637I). GM00637I cells were treated with 1 mm 2‐deoxyglucose, 0.25 mM AICAR, or 1 mm phenformin for 24 h. Lysates were subjected to western blotting with anti‐FANCD2, phospho‐AMPK alpha1 (T172), and AMPK alpha and beta‐actin. In FANCD2 blots, the position of monoubiquitinated FANCD2 (Ub‐FANCD2) is indicated by an arrow. (B) AICAR treatment induces formation of FANCD2 nuclear foci in GM00637I fibroblasts. Cells grown on coverslips in 12‐well plates were treated with 0.25 mm AICAR for 24 h. Cells were immunostained with FANCD2 antibody and Alexa 488‐conjugated anti‐rabbit secondary antibody. FANCD2 foci were visualized by confocal microscopy. Representative images are shown at the top. The number of foci per cell was counted and plotted for ≥ 20 cells (bottom panel). The values represent the mean ± SEM (Student's t‐test, ***P < 0.001). (C) AICAR treatment induces FANCD2 monoubiquitination in Caki‐1 cells. Caki‐1 cells were treated with 0.25 mm AICAR for 24 h and monoubiquitination of FANCD2 was monitored as in (A). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28174693), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: beta-Catenin Antibody [NBP1-32239] -

Roles of P38 mitogen-activated protein kinase (MAPK) in the DFO-mediated up-regulate of HIF-1 alpha protein in APPsw cells. (A) APPsw were exposed to 100 μM Fe, 100 μM DFO, or both combined for 24 h. Whole cell lysates were prepared and subjected to analysis for P38 or GAPDH protein. (B) Western blot analysis revealed that strong phosphorylation of P38 MAPK was detected in the DFO-treated cells, whereas no significant changes were observed in cells treated Fe alone compared with control. There were not statistical changes in the levels of P38 MAPK among the groups. The data represent the mean ± S.E. of three independent experiments. *p < 0.05, **p < 0.01 compared with the control; #p < 0.05, ##p < 0.01 with respect to the Fe treatment group. (C–E) APPsw cells were pretreated without or with SB203580 (10 μM) for 2 h and then treated without or with DFO for additional 22 h in the absence or presence of the inhibitor. Immunoblotting showed that DFO treatment significantly increased the levels of p-P38 MAPK compared with the control group, whereas the increase was significantly ameliorated by SB203580. Furthermore, the DFO-mediated up-regulation of HIF-1 alpha protein was greatly inhibited by SB203580. The data represent the mean ± S.E. (n = 3). **p < 0.01 compared with the control; ##p < 0.01 compared to the values of DFO treatment group (two-way ANOVA with Post hoc Fisher’s PLSD). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/26082716), licensed under a CC-BY license. Not internally tested by Novus Biologicals.